Evidence map›Paper›PMID 35730941›Full record

ArticleMicrobiology spectrum2022

Identification of a Novel Two-Peptide Lantibiotic from Vagococcus fluvialis.

Zuzana Rosenbergová, Thomas F Oftedal, Kirill V Ovchinnikov, Thasanth Thiyagarajah, Martin Rebroš, Dzung B Diep

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Design of Novel Saposin-like Bacteriocins Using a Hybrid Approach.Probiotics and antimicrobial proteins · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Zuzana Rosenbergová *Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Thomas F Oftedal *Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.ORCID 0000-0003-4182-3831
Kirill V OvchinnikovFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.ORCID 0000-0002-4767-8666
Thasanth ThiyagarajahFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Martin RebrošInstitute of Biotechnology, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia.
Dzung B DiepFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.ORCID 0000-0001-7661-5501
Norwegian University of Life Sciences · NOSlovak University of Technology in Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections caused by multiresistant pathogens have become a major problem in both human and veterinary medicine. Due to the declining efficacy of many antibiotics, new antimicrobials are needed. Promising alternatives or additions to antibiotics are bacteriocins, antimicrobial peptides of bacterial origin with activity against many pathogens, including antibiotic-resistant strains. From a sample of fermented maize, we isolated a Vagococcus fluvialis strain producing a bacteriocin with antimicrobial activity against multiresistant Enterococcus faecium. Whole-genome sequencing revealed the genes for a novel two-peptide lantibiotic. The production of the lantibiotic by the isolate was confirmed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry, which revealed distinct peaks at 4,009.4

Indexed as

BacteriocinsVancomycin-Resistant EnterococciAnti-Bacterial AgentsEnterococcaceaePeptidesAnti-Bacterial AgentsBacteriocinsPeptidesantimicrobialbacteriocinlantibioticpore formationvagococcin TVagococcus

Identifiers

PMID35730941
PMCPMC9431498
OpenAlexW4283312800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.